LAMIVUDINE,ZIDOVUDINE

Lamivudine and Zidovudine is a combination medication containing the active ingredients lamivudine and zidovudine. It is indicated for the treatment of HIV-1 infection in combination with other antiretroviral medicines. Human immunodeficiency virus (HIV-1) infects and destroys immune system cells; consequently, the body's ability to resist infections diminishes and, in advanced disease, may lead to death. Patients with neutropenia (reduced white blood cells) or anaemia (reduced red blood cells) should not receive zidovudine or lamivudine. Inform your doctor if you have liver disease, including hepatitis B or C, renal disease, or are obese. Lamivudine and zidovudine received separate approvals from the U.S. Food and Drug Administration (FDA). Lamivudine received FDA approval on November 17, 1995. Zidovudine received FDA approval on March 19, 1987.

lamivudine and Zidovudine are used in the treatment of HIV–1 infection.

Lamivudine and Zidovudine capsules or tablets is taken orally. The medication is usually taken once a day, with or without food, as directed by your healthcare provider. Swallow the capsule or tablet whole without crushing or chewing it.

lamivudine and Zidovudine can cause side effects such as nausea, vomiting, headache, diarrhea, fatigue, muscle pain, insomnia, rash, loss of appetite, abdominal pain, and joint pain. Although less common, these medications can also lead to serious side effects, such as severe allergic reactions, lactic acidosis, hepatotoxicity, blood disorders, and pancreatitis.

Lamivudine and zidovudine carry several important warnings. These include the risk of lactic acidosis and hepatomegaly with steatosis, hematologic toxicity, hepatotoxicity in individuals with pre-existing liver disease, immune reconstitution syndrome, potential drug interactions, pancreatitis, mitochondrial toxicity, immune system changes, hypersensitivity reactions, and considerations for use during pregnancy.

Inform your healthcare provider about all medications, including over-the-counter drugs and herbal supplements, to avoid potential drug interactions. Additionally, follow your healthcare provider's instructions regarding dosage and monitoring. Regularly attend check-ups to assess your response to the medications and address any concerns promptly.

Lamivudine and zidovudine require consultation with a healthcare provider before use. Inform your doctor of any unusual side effects experienced during treatment. Disclose any history of liver disease, including hepatitis B or C, kidney disease, or obesity. Women who are pregnant or breastfeeding must consult their doctor prior to use. Direct any health-related questions about this medication to your healthcare provider.

KD Tripathi, Essentials of Medical Pharmacology, Antiviral drugs, 7th edition, 2013, 806 - 811. Goodman & Gilman’s, The Pharmacological Basis of Therapeutics, Antiretroviral agenteatment of HIV infection, 12th edition, 2011, 1632-1634. Milpharm Limited, Electronic medicines compendium (EMC), [ Revised on September 2020] [ Accessed on 16th May 2023], https://www.medicines.org.uk/emc/files/pil.2998.pdf ViiV Healthcare, US Food and Drug Administration, [ Revised on September 2015] [ Accessed on 16th May 2023], https://www.accessdata.fda.gov/drugsatfda_docs/...